Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating
Personalis, Inc. has received a Buy rating due to its strong performance in cancer testing. The company's NeXT Personal Dx MRD test is gaining traction, supported by recent expansions in Medicare coverage. Despite facing a projected net loss in 2026, the company anticipates significant growth in clinical test volume this year.
- ▪Personalis, Inc. is rated Buy based on strong momentum in its NeXT Personal Dx MRD test.
- ▪The company expects to conduct 43,000 to 45,000 tests this year.
- ▪Recent Medicare coverage expansions are contributing to the company's growth.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4909822-personalis-initiating-coverage-of-cancer-testing-biotech-with-a-buy-rating"},"author":{"@type":"Person","name":"Edmund…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
